(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds- Watch SpaceX launch powerful ocean-mapping satellite for Europe and NASA early Nov. 17
- Instructions to Grasp the Innovation Behind 5G Pinnacles\
- The Advancement and Effect of Dental Embed Innovation on Oral Wellbeing
- What's an atmospheric river? AP explains the weather phenomenon
- Select Your Go-To Bluetooth Earphones
- Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- The most effective method to Guarantee Scholastic Honesty in Web-based Degrees
- The most effective method to Recognize an Excellent Lab Precious stone
